All USA USA Territories: American Samoa (USA); Guam (USA); Puerto Rico (USA); Virgin Islands (USA); Northern Mariana Islands (USA); USA Compact Free Associations:The Federated States of Micronesia (USA) Marshall Islands (USA) Republic of Palau (USA) International, Israel and Canada.
Grants to USA, Canada, and International medical professional schools, healthcare institutions, and professional associations to further the education of health professionals. The purpose of the program is to advance the knowledge of healthcare professionals on non-alcoholic steatohepatitis in at-risk populations.
General Area of Interest for this RFP:
Projects that will be considered for Pfizer support will focus on educating healthcare professionals, with a focus on general practitioners and non-liver specialists, on NASH to:
Increase awareness of patients at risk for NASH and enable appropriate and early diagnosis to enable appropriate management to help prevent disease progression
Establish a call to action to raise awareness of NASH in at risk and underdiagnosed minority and underserved populations with NASH to reduce disparities and delayed diagnosis
Explore strategies that empower patients to play an active role in understanding NASH and decision making regarding available diagnostic and disease management options
Proposals that include/address the following will be prioritized:
Activities for healthcare professionals that also include educational materials or resources for patients
Patient participation in the development of the initiative
Applicant Eligibility Criteria
• Only organizations are eligible to receive grants, not individuals or medical practice groups.
• The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education, patient education, and/or healthcare improvement.
• If the project involves multiple departments within an institution and/or between different institutions / organizations / associations. All institutions must have a relevant role and the requesting organization must have a key role in the project.
• For projects offering continuing education credit, the requesting organization must be accredited.
It is not Pfizer's intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.
• RFP release date: May 4, 2023
• Grant Application due date: June 22, 2023
Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5).
• Anticipated Grant Award Notification Date: August 2023
• Grants will be distributed following a fully executed agreement.
• Anticipated Project Start Dates: December 2023
Number of Grants
Estimated Size of Grant
Individual projects requesting up to $100,000 USD will be considered.
If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Jessica Romano (Jessica.Romano@pfizer.com), with the subject line “Early Identification and Diagnosis of NASH in At-Risk Populations IME RFP.”